
Aurinia Pharmaceuticals AUPH
$ 16.08
3.01%
Annual report 2025
added 02-26-2026
Aurinia Pharmaceuticals Total Non Current Liabilities 2011-2026 | AUPH
Annual Total Non Current Liabilities Aurinia Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 41.9 M | 26 M | 16 M | 13.1 M | 9.99 M | 4.44 M | 3.8 M | 2.61 M | 5.78 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.9 M | 2.61 M | 13.7 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 8.41 | 4.73 % | $ 230 M | ||
|
Ardelyx
ARDX
|
50.9 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
226 M | $ 752.35 | 0.79 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.83 | 0.85 % | $ 3.03 B | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
BioCardia
BCDA
|
1.3 M | $ 1.2 | -0.04 % | $ 8 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 9.6 | 6.37 % | $ 1.98 B | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
802 M | $ 9.48 | -3.27 % | $ 613 M | ||
|
BioVie
BIVI
|
62.5 K | $ 1.45 | 2.09 % | $ 2.14 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
BioLineRx Ltd.
BLRX
|
8.22 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
BioMarin Pharmaceutical
BMRN
|
635 M | $ 56.49 | 1.78 % | $ 10.8 B | ||
|
BioNTech SE
BNTX
|
341 M | $ 92.3 | 1.23 % | $ 27.2 B | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
332 | $ 3.04 | 1.54 % | $ 259 M | ||
|
BioXcel Therapeutics
BTAI
|
1.4 M | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Cabaletta Bio
CABA
|
43.9 M | $ 3.2 | 7.94 % | $ 322 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 3.21 | 4.56 % | $ 6.98 B | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Catalyst Biosciences
CBIO
|
981 K | $ 19.97 | 2.94 % | $ 1.78 B | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Codexis
CDXS
|
28.2 M | $ 1.97 | 7.97 % | $ 172 M | ||
|
Cerus Corporation
CERS
|
58.1 M | $ 1.91 | 2.42 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
277 M | $ 15.4 | 6.72 % | $ 928 M | ||
|
Coherus BioSciences
CHRS
|
189 M | $ 1.75 | 0.87 % | $ 205 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B |